Loading viewer...
investor_presentation
Format: PDF investor_presentation
37th Annual J.P . Morgan Healthcare Conference Howard Robin President & CEO January 8, 2019
J.P . Morgan Healthcare Conference
January 8, 20192This presentation includes forward -looking statements regarding Nektar’s proprietary drug
candidates, the timing of the start and conclusion of ongoing or planned clinical trials, the timing
and outcome of regulatory decisions, and future availability of clinical trial data. Actual results
could differ materially and these statements are subject to important risks detailed in Nektar's
filings with the SEC including the Form 10 -Q filed on November 8, 2018. Nektar undertakes no
obligation to update forward -looking statements as a result of new information or otherwise.3
Focus of Nektar Pipeline
Target the innate and
adaptive immune systemImmuno -oncology
NKTR -255 (Wholly -Owned)
IL-15 Receptor Agonist
IND in firsthalf of 2019
(Co-Develop and Co -Promote)
CD122 -Biased Agonist
Multiple Solid Tumors
NKTR -262 (Wholly -Owned)
Multiple Solid Tumors
Phase 1/2 studies ongoingA next generation opioid
molecule Chronic Pain
NKTR -181 (Wholly -Owned)
Chronic Low Back Pain
May 29, 2019 PDUFA dateHarness the immune
system to fight auto -
immune disease Immunology
NKTR -358 (Co-Promote)
T Regulatory Cell Stimulator
Rheumatoid Arthritis
MAD in Lupus patients
Initiated April 2018
Preview truncated — download the full document for the complete content.
conference
28 Pages
investor_presentation
40 Pages
Wärtsilä
Mettler-Toledo International Investor Presentation — November 2022
investor_presentationinvestor_presentation
10 Pages
Mettler-Toledo International Inc.